Highlights Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
0.814 ^USD	-2.98%		-4.55%	+59.61%

06/05	Oppenheimer Upgrades Chemomab Therapeutics to Outperform	MT
10/04	Transcript : Chemomab Therapeutics Ltd. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/03	CI
Chemomab Therapeutics Ltd. Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	30/01	CI
Chemomab Therapeutics Ltd. Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	03/01	CI
Chemomab Therapeutics Ltd. Announces U.S. Food and Drug Administration Grants CM-101 Fast Track Designation for Treatment in Adult Patients of Primary Sclerosing Cholangitis	15/11	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis At 2023 Roth MKM Healthcare Opportunities Conference	28/23/28	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis	28/23/28	CI
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023	21/23/21	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Chemomab Therapeutics Ltd. Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of Cm-101 in Patients with Systemic Sclerosis	21/23/21	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Chemomab Therapeutics, Ltd Reports Top-Line Results from Its Phase 2A Trial Assessing CM-101, Its First-In-Class CCL24-Neutralizing Monoclonal Antibody, in Non-Alcoholic Steatohepatitis Patients	03/23/03	CI
Chemomab Therapeutics, Ltd. Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis	21/22/21	CI
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy	30/22/30	PR
Chemomab Announces Appointment of Mitchell L. Jones, as Vice President of Corporate Development & Strategy	30/22/30	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19	09/22/09	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Earnings Flash (CMMB) CHEMOMAB THERAPEUTICS Posts Q2 Loss $-0.03, vs. Street Est of $-0.18	12/22/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Highlights

Filters